drugset / Trial / NCT01456130
Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes
NaSingle-groupOpen-label
Summary
The purpose of this study is to evaluate the safety and efficacy of alogliptin as an add-on to a rapid-acting insulin secretagogue (medicine that stimulates insulin release) in type 2 diabetic patients with inadequate blood glucose control despite treatment with a rapid-acting insulin secretagogue as well as diet and exercise therapies.
Timeline
- Start
- 2011-11
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alogliptin | Unknown | 12.5 mg | Oral |
| Subject | Alogliptin | Unknown | 25 mg | Oral |
| Background | Mitiglinide | Small molecule | 5 mg | — |
| Background | Mitiglinide | Small molecule | 10 mg | — |
| Background | Nateglinide | Small molecule | 30 mg | — |
| Background | Nateglinide | Small molecule | 90 mg | — |